ABOUT
ABOUT US
LEADERSHIP
Executive Team
MILESTONE
PRODUCT
ALL
Iron Deficiency Anemia
Emergency Care
Respiratory
PIPELINE
PIPELINE
Respiratory
Pain Management
Emergency Care
Iron Deficiency Anemia
PARTNERSHIP
NEWS
ALL
Company News
Strategic Cooperation Agreement with SHAPHAR
Nuance Pharma advances Rare Disease R&D with CORD
优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
优锐医药受邀出席中关村肾病血液净化创新联盟 “峥嵘五年 再续华章” 五周年庆典
Bentrio™鼻喷剂 活力上线 亮相中国香港！
优锐医药恩塞芬汀中国III期临床试验 全国研究者会顺利召开
优锐医药助力2023中国医疗健康峰会
Nuance Pharma Attended The 3rd BioCentury-BayHelix East-West Biopharma Summit in Singapore
Media
Nuance Pharma Closes Series D Financing
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Nuance Pharma's Partner Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
Partner News
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
INVESTOR
CAREER
PROFILE
CONTACT